Mr. Harbaugh will be responsible for all financial aspects of NuVasive, including its financial planning and analysis, tax and treasury. He will be part of the company’s global executive team and report to CEO J. Christopher Barry.
Prior to joining NuVasive, Mr. Harbaugh was president of the specialty generics business at Mallinckrodt plc. He also spent five years as the company’s CFO. Beyond Mallinckrodt, Mr. Harbaugh spent time in financial management roles at Covidien, including CFO.
Mr. Harbaugh took over the CFO role on Jan. 2. Mr. Asarpota plans to stay with NuVasive in an advisory role through May; he will then provide ongoing consulting services through September.
More articles on spine devices:
SeaSpine launches midline posterior fixation system — 3 insights
Stryker in 2019: 6 things to know
14 spine devices receive FDA 510(k) clearance
